RBM22 and neoplasm: In conclusion, we identified 12 RBPs (RPS3, RBM22, EIF2S1, DHX8, RBM8A, UPF1, YBX1, SNRPE, SF3A1, U2AF1, SUPT6H, EIF3G) with strong tumor proliferative effects without any marked changes in expression in colorectal, pancreatic and esophageal cancer using the functional assessment of RBPs with an siRNA library focused on cancer growth change.